To assess the translatability of our findings to clinically relevant advanced-stage HCC, we next assessed the in vivo activity of LNP-CTNNB1 in late-stage disease CTNNB1-mutated HCC models, including both the β-N and β-M models. Here, CTNNB1 is linked to hepatocellular carcinoma.